A Sydney lawyer has been ordered to pay the costs of a property dispute after a judge found his conduct meant the case was âdoomed to failâ and caused the costs of the litigation to be wasted.
The High Court has declined to weigh in on a dispute between a retired law firm partner and the ATO over tax on $182,000 in goodwill payments the lawyer received upon exiting the firm’s partnership.
South Korean biosimilars company Samsung Bioepis has sued to invalidate two patents held by a German competitor for a pre-filled syringe to treat age-related eye diseases, as generic drug makers race for a piece of the lucrative eye drug market.
The Indian government has lodged an appeal after a judge found it can’t avoid a $111.3 million arbitral award in a dispute with three Mauritian companies that invested in Indian satellites.
Fleet management company FleetPartners has been stung with a shareholder class action over a revised 2019 earnings guidance that doomed its planned merger with McMillan Shakespeare.
The Australian Securities and Investments Commission has filed its first-ever case over internal dispute resolution regulations, targeting Telstra Super over its handling of customer complaints.
A human rights group has lost its legal bid to compel the federal government to bring home Australians stuck in Syrian camps, with a a judge finding the Minister for Home Affairs has âno controlâ over their detention.
The Office of the Australian Information Commissioner has brought civil penalty proceedings accusing pathology services provider Australian Clinical Labs of failing to take steps to prevent a February 2022 data breach that affected millions of patients.
Tiwi Islanders have won an eleventh hour bid to halt all work on Santos’ Barossa gas export pipeline for one week, with a judge finding construction could cause “irreparable damage” to underwater cultural heritage.
Novartis unit Sandoz AG has lost its bid to revoke Bayerâs patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giantâs patents were valid.